Boston Scientific: New FDA approvals and medtech leadership
Boston Scientific is reasserting itself as a trailblazer in the medtech sector in 2025, riding a wave of regulatory wins and breakthrough product launches. The company’s relentless focus on innovation, patient outcomes, and global expansion is paying off—reflected in rising revenues, growing market share, and a portfolio brimming with new FDA-approved therapies. At the heart of its momentum are two major narratives: the success of its FARAPULSE™ Pulsed Field Ablation (PFA) System in cardiac electrophysiology and the acquisition and rapid scale-up of disruptive technologies in pain management and vascular intervention. Here’s how Boston Scientific is leading medtech’s next era.
🔔 Don’t miss out!
Add winvestacrisps@substack.com to your email list so our updates never land in spam
Keep reading with a 7-day free trial
Subscribe to Winvesta Crisps to keep reading this post and get 7 days of free access to the full post archives.